Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | APEX1 | P27695 | 1/20 | 0.43 |
| ▸ | DPP4 | P27487 | 6/20 | 0.41 |
| ▸ | BRD4 | O60885 | 1/20 | 0.38 |
| ▸ | BRD2 | P25440 | 1/20 | 0.38 |
| ▸ | GRM5 | P41594 | 4/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | HTR5A | P47898 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4704758 | 1.00 | CYP3A4 (0.43) | CYP3A4TSHRTDP1MAPTAPEX1 | |
| SCHEMBL1189733 | 1.00 | CYP3A4 (0.43) | CYP3A4TSHRTDP1MAPTAPEX1 | |
| Hydrochloric Acid SCHEMBL2458514 | 0.98 | CYP3A4 (0.42) | CYP3A4TSHRTDP1MAPTAPEX1 | |
| Hydrochloric Acid SCHEMBL2458517 | 0.98 | CYP3A4 (0.42) | CYP3A4TSHRTDP1MAPTAPEX1 | |
| SCHEMBL2386749 | 0.93 | — | — | |
| SCHEMBL2386755 | 0.93 | — | — | |
| SCHEMBL30324543 | 0.93 | — | — | |
| SCHEMBL15124193 | 0.93 | — | — | |
| Hydrochloric Acid SCHEMBL31043356 | 0.91 | CYP3A4 (0.43) | CYP3A4TSHRTDP1MAPTAPEX1 | |
| Hydrochloric Acid SCHEMBL2458091 | 0.91 | CYP3A4 (0.43) | CYP3A4TSHRTDP1MAPTAPEX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115916207-A | Five-membered and six-membered heterocyclic compounds and application thereof as protein receptor kinase inhibitors | 轶诺(浙江)药业有限公司 | 2023-04-04 | — | — | CN | disclosed |
| WO-2022037694-A1 | A CLASS OF FIVE- AND SIX-MEMBERED HETEROCYCLIC COMPOUNDS AND USE THEREOF AS PROTEIN RECEPTOR KINASE INHIBITORS | 轶诺(浙江)药业有限公司 | 2022-02-24 | — | — | WO | disclosed |
| US-7220856-B2 | Substituted quinoline CCR5 receptor antagonists | SCHERING AKTIENGESELLSCHAFT (DE) | 2007-05-22 | — | — | US | disclosed |
| EP-1534681-A1 | SUBSTITUTED QUINOLINE CCR5 RECEPTOR ANTAGONISTS | SCHERING AKTIENGESELLSCHAFT (DE) | 2005-06-01 | — | — | EP | disclosed |
| US-20040072818-A1 | Substituted quinoline CCR5 receptor antagonists | SCHERING AKTIENGESELLSCHAFT (DE) | 2004-04-15 | — | — | US | disclosed |
| WO-2004002960-A1 | SUBSTITUTED QUINOLINE CCR5 RECEPTOR ANTAGONISTS | SCHERING AKTIENGESELLSCHAFT (DE) | 2004-01-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040072818-A1 | Substituted quinoline CCR5 receptor antagonists | CCR5, CXCR3, CCR2 | CYP3A4 662/4885TSHR 667/4885TDP1 3234/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.